Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
出版年份 2021 全文链接
标题
Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
作者
关键词
-
出版物
Journal of Personalized Medicine
Volume 11, Issue 3, Pages 217
出版商
MDPI AG
发表日期
2021-03-18
DOI
10.3390/jpm11030217
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
- (2021) Rangarirai Makuku et al. Journal of Immunology Research
- Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy
- (2020) Brandon S. Imber et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications
- (2020) Pierre Decazes et al. Cancers
- ImmunoPET: Concept, Design, and Applications
- (2020) Weijun Wei et al. CHEMICAL REVIEWS
- PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
- (2020) Wei Xie et al. Current Hematologic Malignancy Reports
- Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives
- (2020) Angela Sardaro et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
- (2020) Fatima-Zohra Mokrane et al. RADIOLOGY
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
- (2020) Federico Simonetta et al. CLINICAL CANCER RESEARCH
- Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism
- (2020) Larissa B. Costa et al. RADIOGRAPHICS
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
- (2019) Georg Maschmeyer et al. LEUKEMIA
- Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
- (2019) Laurent Dercle et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma
- (2019) L. Quéro et al. Cancer Radiotherapie
- Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
- (2019) Yada Kanjanapan et al. CANCER
- Neurological toxicities associated with chimeric antigen receptor T-cell therapy
- (2019) Daniel B Rubin et al. BRAIN
- Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma
- (2019) Jiasheng Wang et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Immunotherapy in Hodgkin Lymphoma: The Road Ahead
- (2019) Stephen M. Ansell TRENDS IN IMMUNOLOGY
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- Early 18F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab
- (2019) Aiping Chen et al. JOURNAL OF NUCLEAR MEDICINE
- Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
- (2019) Matthias Mulazzani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers
- (2018) Cédric Rossi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma
- (2018) Guillaume Manson et al. BLOOD
- Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma
- (2018) Laurent Dercle et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Positron emission tomography of adoptively transferred chimeric antigen receptor T cells with Zirconium-89 oxine
- (2018) Michael Ryan Weist et al. JOURNAL OF NUCLEAR MEDICINE
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma
- (2018) Qian Qin et al. RADIATION RESEARCH
- 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors
- (2018) Angelo Castello et al. LEUKEMIA & LYMPHOMA
- In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET
- (2018) Stefanie Pektor et al. EJNMMI Research
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor –T-cell therapy in B-cell non-Hodgkin lymphomas
- (2018) Nirav N. Shah et al. CYTOTHERAPY
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
- (2018) Christos Sachpekidis et al. MELANOMA RESEARCH
- Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors
- (2017) Christian Baues et al. Immunotherapy
- Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation
- (2017) Girolamo Ranieri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor
- (2017) Laurent Dercle et al. JOURNAL OF NUCLEAR MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Pediatric Hodgkin Lymphoma
- (2017) Cristina Ferrari et al. MEDICINE
- FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
- (2017) Yvette L. Kasamon et al. ONCOLOGIST
- Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
- (2017) Yvonne W. S. Jauw et al. PLoS One
- Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
- (2017) Gary X. Wang et al. RADIOGRAPHICS
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
- (2016) Bruce D. Cheson et al. BLOOD
- PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
- (2016) S. F. Barrington et al. BLOOD
- Nivolumab in the Treatment of Hodgkin Lymphoma
- (2016) Stephen M. Ansell CLINICAL CANCER RESEARCH
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Immune-priming of the Tumor Microenvironment by Radiotherapy
- (2015) Vafa Shahabi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
- (2015) Kobe Reynders et al. CANCER TREATMENT REVIEWS
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
- (2015) Kristoff Muylle et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- FDG PET/CT in cancer: comparison of actual use with literature-based recommendations
- (2015) Henrik Petersen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma
- (2015) Yolanda D. Tseng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events
- (2015) Jennifer J. Kwak et al. RADIOGRAPHICS
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Immunologic pathomechanism of Hodgkin's lymphoma
- (2013) Adam Jona et al. EXPERIMENTAL HEMATOLOGY
- The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
- (2013) Emily F. Stamell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift?
- (2013) L. Kostakoglu et al. JOURNAL OF NUCLEAR MEDICINE
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET
- (2012) Saiyada N. F. Rizvi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- (2012) Scott M. Knowles et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma
- (2011) Xingchen Wu et al. LEUKEMIA & LYMPHOMA
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence
- (2008) Kayako Isohashi et al. ANNALS OF NUCLEAR MEDICINE
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More